Given TGF-β’s dual role in promoting lung fibrosis and influencing the tumor microenvironment, inhibiting this pathway is considered a promising strategy for reducing lung toxicity while enhancing the effectiveness of immunotherapy [78,79]. The gene discussed is TGFB1; the disease is fibrosis.